Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anteris Technologies Global Corp. (AVR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, giving investors a detailed view of its structural heart business and capital markets activity. As a medical instruments and supplies company focused on the DurAVR Transcatheter Heart Valve (THV) System, Anteris uses its filings to describe its technology, clinical programs and financial profile.
Through registration statements such as the Form S‑1, readers can review the company’s business overview, including its description of DurAVR THV as a balloon‑expandable biomimetic aortic valve, the role of its proprietary ADAPT tissue technology and the design of the ComASUR balloon‑expandable delivery system. These filings also outline the PARADIGM Trial, a global prospective randomized controlled trial comparing DurAVR THV to commercially available TAVR devices, and explain how the trial is intended to support a future Premarket Approval application and CE Mark progress.
Current reports on Form 8‑K document material events such as FDA IDE approval for PARADIGM, first patient enrollment and treatment in the pivotal trial, clinical data presentations, capital raising transactions involving common stock, CHESS Depositary Interests and warrants, and other corporate developments. Definitive proxy statements on Schedule 14A provide detail on the annual meeting agenda, director elections, equity incentive awards and stockholder voting procedures.
On Stock Titan, these filings are updated in near real time from EDGAR and can be paired with AI‑generated summaries that highlight key points from lengthy documents. Users can quickly locate quarterly reports on Form 10‑Q, annual reports on Form 10‑K (when filed), 8‑K event disclosures and registration statements, and use AI‑assisted explanations to understand complex sections such as risk factors, clinical trial descriptions, capital structure and equity compensation proposals.
For those analyzing AVR, the filings page offers a structured way to follow how Anteris presents its structural heart strategy, clinical evidence plans and financing arrangements to regulators and investors.
Anteris Technologies Global Corp. director Gregory S. Moss reported receiving two grants of restricted stock units tied to the company’s common stock. One grant covers 52,742 restricted stock units, each representing a right to receive one share of common stock.
These 52,742 units vest in three approximately equal annual installments on June 7, 2026, 2027 and 2028, subject to his continued service. A second grant of 13,821 restricted stock units also represents one share of common stock per unit and vests on the earlier of the first anniversary of the grant date and the next annual stockholders meeting, subject to continued service.
Anteris Technologies Global Corp. is registering 9,103,796 shares of common stock for resale by existing investors. The shares consist of 2,346,936 already-issued shares, 2,346,936 shares issuable upon exercise of common stock warrants, 2,079,962 shares underlying CHESS Depositary Interests (CDIs), and 2,329,962 shares issuable upon exercise of CDI warrants. These securities were issued in an October–November 2025 private placement. Anteris will not receive proceeds from stockholder resales but could receive up to approximately $40.4 million if all related warrants are exercised at $7.50 per share for common stock warrants and A$11.50 per CDI for CDI warrants. As of September 30, 2025, 36,062,370 shares of common stock were outstanding. Anteris is a development-stage structural heart company focused on its DurAVR® transcatheter heart valve and the global PARADIGM pivotal trial in severe aortic stenosis; prior audited financials include an explanatory paragraph about substantial doubt regarding its ability to continue as a going concern.
Anteris Technologies Global Corp. reported that it has presented new clinical information on its DurAVR® Transcatheter Heart Valve (THV). The company issued an ASX announcement on November 16, 2025 (November 17, 2025 AEDT) and a press release on November 17, 2025 summarizing 30-day clinical outcomes in one hundred severe aortic stenosis patients with small aortic annuli treated with DurAVR THV. This information is being furnished to regulators rather than formally filed, meaning it is shared for transparency but does not carry the same legal status as filed financial statements.
Anteris Technologies Global Corp. (AVR) furnished quarterly results materials. The company submitted an 8-K noting it filed its Form 10-Q for the quarter ended September 30, 2025, and furnished an accompanying ASX Results Announcement and an ASX Announcement. These materials include unaudited and other historical financial information for the quarter. The exhibits (99.1 and 99.2) are furnished under Item 2.02 and are not deemed filed or incorporated by reference unless a later filing expressly states otherwise.
Anteris Technologies Global Corp. (AVR) reported a third‑quarter net loss and flagged going‑concern uncertainty. Net sales were $429 thousand, while operating loss reached $22.3 million. R&D expense was $16.8 million as the company advanced the DurAVR® transcatheter heart valve program and pivotal PARADIGM Trial preparations. Selling, general and administrative expense was $5.8 million.
The company recorded a net loss after income tax of $22.2 million for the quarter and $65.2 million year‑to‑date. Cash, cash equivalents and restricted cash were $9.1 million as of September 30, 2025, with net cash used in operating activities of $59.3 million for the nine months, leading management to note “substantial doubt” about continuing as a going concern. Stockholders’ equity was $3.7 million.
Subsequent to quarter‑end, Anteris completed a private placement generating approximately $25.2 million in gross proceeds and received key regulatory milestones for its PARADIGM Trial, including the first European clearance in Denmark and FDA approval to initiate the U.S. IDE study. The trial is designed to support a future PMA and parallel CE Mark efforts.
Anteris Technologies Global Corp. (AVR) announced its 2025 Annual Meeting of Stockholders to be held on December 3, 2025 at 5:00 p.m. Central time, in Brisbane and via webcast at www.virtualshareholdermeeting.com/AVR2025. Stockholders of record as of October 30, 2025 may attend, vote, and submit questions. Holders of CHESS Depositary Interests (CDIs) may attend and direct votes in advance through CHESS Depositary Nominees but are not eligible to vote during the meeting.
Thirteen proposals are up for vote, including electing John Seaberg and Gregory Moss as Class I directors, ratifying KPMG as independent auditor for the fiscal year ending December 31, 2025, approving equity awards tied to the IPO—such as 1,000,000 RSUs to Wayne Paterson and RSU grants to non‑employee directors—and approving adjustments and amendments to previously granted stock options under ASX Listing Rule 6.23.4.
Voting mechanics: Proposal One is decided by plurality; most others require a majority of shares present and entitled to vote; Proposal Two is a routine matter permitting broker discretionary voting. Shares outstanding were 38,409,506 as of the record date. The Board recommends voting FOR all proposals.
Anteris Technologies Global Corp. furnished a Regulation FD update via Form 8‑K announcing that the U.S. FDA approved its DurAVR® Transcatheter Heart Valve Global Pivotal Trial, known as the PARADIGM Trial. The company attached the related press release as Exhibit 99.1, and the information was furnished, not filed, under the Exchange Act.
Anteris Technologies Global Corp. (AVR) announced its 2025 Annual Meeting for December 3, 2025 at 5:00 p.m. Central time in Brisbane with a concurrent webcast at www.virtualshareholdermeeting.com/AVR2025. The record date is October 30, 2025.
Stockholders will vote on 13 proposals. Key items include electing two Class I directors (John Seaberg and Gregory Moss) and ratifying KPMG as independent auditor for the fiscal year ending December 31, 2025. Several equity awards are up for approval under ASX Listing Rule 10.14: 1,000,000 RSUs to Wayne Paterson, 83,333 RSUs to John Seaberg, 41,666 RSUs to Stephen Denaro, and 52,742 RSUs each to Gregory Moss and David Roberts. Additional annual director grants by value include $250,000 to Seaberg, $125,000 to Denaro, and $61,644 each to Moss and Roberts.
Two proposals under ASX Listing Rule 6.23.4 seek approval for adjustments to certain option exercise prices and amendments to prior option terms. The Board recommends voting FOR all proposals. Holders of CHESS Depositary Interests receive notice and may vote in advance by directing CDN; CDI holders cannot vote during the meeting unless appointed as CDN’s proxy.